
Pentaethylene glycol
CAS No. 4792-15-8
Pentaethylene glycol( —— )
Catalog No. M33460 CAS No. 4792-15-8
Pentaethylene glycol (3,6,9,12-Tetraoxatetradecane-1,14-diol) is a PROTAC linker belonging to the PEG class and can be used to synthesize PROTAC molecules.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NamePentaethylene glycol
-
NoteResearch use only, not for human use.
-
Brief DescriptionPentaethylene glycol (3,6,9,12-Tetraoxatetradecane-1,14-diol) is a PROTAC linker belonging to the PEG class and can be used to synthesize PROTAC molecules.
-
DescriptionPentaethylene glycol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
-
In VitroPROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
-
In Vivo——
-
Synonyms——
-
PathwayPROTACs
-
TargetPROTAC
-
RecptorPROTAC Linker
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number4792-15-8
-
Formula Weight238.28
-
Molecular FormulaC10H22O6
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESOCCOCCOCCOCCOCCO
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562?
molnova catalog



related products
-
FKBP12 PROTAC dTAG-1...
FKBP12 PROTAC dTAG-13 (dTAG-13) is an in vivo-active heterobifunctional adation tag (dTAG) small molecule that engage FKBP12F36V and CRBN.
-
Lenalidomide-Br
Lenalidomide-Br (Compound 41) is an analog of cereblon (CRBN) ligand Lenalidomide for E3 ubiquitin ligase, and is used in the recruitment of CRBN protein.
-
Amino-PEG11-amine
Amino-PEG11-amine, a PEG-based (12 units) PROTAC linker used to combine two mono diethylstilbestrol (DES)-based ligands, provides an alternative strategy for preparing more selective and active ER antagonists for endocrine therapy of breast cancer.